Abstract
The aim of this study was to determine the effect of immunophenotype on the clinical characteristics and prognosis of 144 adult Chinese patients with non-Hodgkin's lymphomas. Those entities with well-recognised immunophenotype and clinical characteristics were excluded. Significantly more patients with T-cell lymphomas had B symptoms (52 vs. 30%, p = 0.05) and fewer had bulky disease (7 vs. 25%, p = 0.04). Extranodal involvements of liver, spleen, marrow, nasal region and skin were significantly more common in T-cell lymphomas. On the other hand, gastro-intestinal involvement was more commonly seen in B-cell tumours. Induction chemotherapy of comparable intensity was used in treating these patients. The immunophenotype did not appear to affect significantly their prognosis.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Bleomycin / therapeutic use
-
China
-
Cyclophosphamide / therapeutic use
-
Dexamethasone / therapeutic use
-
Doxorubicin / therapeutic use
-
Female
-
Humans
-
Immunophenotyping
-
Leucovorin / therapeutic use
-
Lomustine / therapeutic use
-
Lymphoma, B-Cell* / drug therapy
-
Lymphoma, B-Cell* / mortality
-
Lymphoma, B-Cell* / pathology
-
Lymphoma, T-Cell* / drug therapy
-
Lymphoma, T-Cell* / mortality
-
Lymphoma, T-Cell* / pathology
-
Male
-
Methotrexate / therapeutic use
-
Middle Aged
-
Prednisone / therapeutic use
-
Procarbazine / therapeutic use
-
Survival Rate
-
Vinblastine / therapeutic use
-
Vincristine / therapeutic use
Substances
-
Bleomycin
-
Procarbazine
-
Vincristine
-
Vinblastine
-
Lomustine
-
Dexamethasone
-
Doxorubicin
-
Cyclophosphamide
-
Leucovorin
-
Prednisone
-
Methotrexate
Supplementary concepts
-
CHOP-B protocol
-
COPP protocol
-
CVPP protocol
-
M-BACOD protocol